Endocrinology status update: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 434: | Line 434: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| class="wikitable" style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
|+ | |||
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}} | ! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}} | ||
! | |||
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}} | ! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}} | ||
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}} | ! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}} | ||
| Line 445: | Line 447: | ||
|- | |- | ||
| rowspan="88" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |CVS | | rowspan="88" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |CVS | ||
| rowspan="5" |'''Diabetes''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Diabetes Landing Page | | style="padding: 5px 5px; background: #F5F5F5;" |Diabetes Landing Page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 477: | Line 480: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |GDM | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Cafer Zorkon | | style="padding: 5px 5px; background: #F5F5F5;" |Cafer Zorkon | ||
| Line 485: | Line 488: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| rowspan="8" |'''Pituitary disorders''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hypopituitarism | | style="padding: 5px 5px; background: #F5F5F5;" |Hypopituitarism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 501: | Line 505: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Pituitary disorders landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Hasan | | style="padding: 5px 5px; background: #F5F5F5;" |Hasan | ||
| Line 509: | Line 513: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hypogonadism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ifeoma | | style="padding: 5px 5px; background: #F5F5F5;" |Ifeoma | ||
| Line 517: | Line 521: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Pituitary apoplexy | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
| Line 525: | Line 529: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Prolactinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Shadi Ebr | | style="padding: 5px 5px; background: #F5F5F5;" |Shadi Ebr | ||
| Line 533: | Line 537: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |GH deficiency | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Ali Akbar | | style="padding: 5px 5px; background: #F5F5F5;" |Usman Ali Akbar | ||
| Line 541: | Line 545: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Acromegaly | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand | | style="padding: 5px 5px; background: #F5F5F5;" |Sogand | ||
| Line 549: | Line 553: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | rowspan="10" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Thyroid disorders landing page | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | | style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | ||
| Line 557: | Line 562: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hyperthyroidism landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | | style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | ||
| Line 565: | Line 570: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Graves Disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | | style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | ||
| Line 573: | Line 578: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Toxic Multinodular goiter | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | | style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | ||
| Line 581: | Line 586: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Goiter | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ali | | style="padding: 5px 5px; background: #F5F5F5;" |Ali | ||
| Line 589: | Line 594: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Toxic adenoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ifrah Fatima | | style="padding: 5px 5px; background: #F5F5F5;" |Ifrah Fatima | ||
| Line 629: | Line 634: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hypothyroidism landing page | | style="padding: 5px 5px; background: #F5F5F5;" |Hypothyroidism landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 637: | Line 643: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Primary hypothyroidism (hypothyroidism) | | style="padding: 5px 5px; background: #F5F5F5;" |Primary hypothyroidism (hypothyroidism) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 645: | Line 652: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hashimoto thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Hashimoto thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 653: | Line 661: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Congenital hypothyroidism/Cretinism | | style="padding: 5px 5px; background: #F5F5F5;" |Congenital hypothyroidism/Cretinism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 661: | Line 670: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Secondary hypothyroidism | | style="padding: 5px 5px; background: #F5F5F5;" |Secondary hypothyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 669: | Line 679: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Thyroiditis Landing page | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroiditis Landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 677: | Line 688: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hashimotos Thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Hashimotos Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 685: | Line 697: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Dequervian Thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Dequervian Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 693: | Line 706: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Riedel's Thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Riedel's Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 701: | Line 715: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Silent Thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Silent Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 709: | Line 724: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Postpartum Thyroiditis | | style="padding: 5px 5px; background: #F5F5F5;" |Postpartum Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 717: | Line 733: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Thyroid nodule | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroid nodule | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 725: | Line 742: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Sick euthyroid syndrome | | style="padding: 5px 5px; background: #F5F5F5;" |Sick euthyroid syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 733: | Line 751: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Thyroid carcinoma landing page | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroid carcinoma landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 741: | Line 760: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Myxedama coma | | style="padding: 5px 5px; background: #F5F5F5;" |Myxedama coma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 749: | Line 769: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Postpartum thyroid dysfunction L. | | style="padding: 5px 5px; background: #F5F5F5;" |Postpartum thyroid dysfunction L. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 757: | Line 778: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Adrenal disorders landing page | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenal disorders landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 765: | Line 787: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Adrenal insufficiency landing page | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenal insufficiency landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 773: | Line 796: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Adrenocortical carcinoma | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenocortical carcinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 781: | Line 805: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |CAH L | | style="padding: 5px 5px; background: #F5F5F5;" |CAH L | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 789: | Line 814: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |21 hydroxylase def | | style="padding: 5px 5px; background: #F5F5F5;" |21 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 797: | Line 823: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |11 hydroxylase def | | style="padding: 5px 5px; background: #F5F5F5;" |11 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 805: | Line 832: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |17 hydroxylase def | | style="padding: 5px 5px; background: #F5F5F5;" |17 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 813: | Line 841: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Addisons disease | | style="padding: 5px 5px; background: #F5F5F5;" |Addisons disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 821: | Line 850: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Incidentiloma | | style="padding: 5px 5px; background: #F5F5F5;" |Incidentiloma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 829: | Line 859: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Pheochromocytoma | | style="padding: 5px 5px; background: #F5F5F5;" |Pheochromocytoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 837: | Line 868: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |P hyperaldosteronism(Conn's) | | style="padding: 5px 5px; background: #F5F5F5;" |P hyperaldosteronism(Conn's) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 845: | Line 877: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hypoaldosteronism | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoaldosteronism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 853: | Line 886: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Cushing's syndrome/Pseudo-Cushing's syndrome | | style="padding: 5px 5px; background: #F5F5F5;" |Cushing's syndrome/Pseudo-Cushing's syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 861: | Line 895: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Secondary Adrenal Insufficiency | | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Secondary Adrenal Insufficiency | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sahar | | style="padding: 5px 5px; background: #F5F5F5;" |Sahar | ||
| Line 869: | Line 904: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |'''MEN type I''' | | style="padding: 5px 5px; background: #F5F5F5;" |'''MEN type I''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 877: | Line 913: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |MEN type 2 | | style="padding: 5px 5px; background: #F5F5F5;" |MEN type 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 885: | Line 922: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Protein energy maln. (Kwashiorkor, Marasmus) | | style="padding: 5px 5px; background: #F5F5F5;" |Protein energy maln. (Kwashiorkor, Marasmus) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 893: | Line 931: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Metabolic syndrome | | style="padding: 5px 5px; background: #F5F5F5;" |Metabolic syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 901: | Line 940: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hypoglycemia | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoglycemia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 909: | Line 949: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Glucaganoma | | style="padding: 5px 5px; background: #F5F5F5;" |Glucaganoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 917: | Line 958: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Insulinoma (hyperinsulism, hyperinsulinemia) | | style="padding: 5px 5px; background: #F5F5F5;" |Insulinoma (hyperinsulism, hyperinsulinemia) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 925: | Line 967: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |DKA | | style="padding: 5px 5px; background: #F5F5F5;" |DKA | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 933: | Line 976: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |HONK/HHS | | style="padding: 5px 5px; background: #F5F5F5;" |HONK/HHS | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 941: | Line 985: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Androgen insensitivity | | style="padding: 5px 5px; background: #F5F5F5;" |Androgen insensitivity | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 949: | Line 994: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Gynecomastia | | style="padding: 5px 5px; background: #F5F5F5;" |Gynecomastia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 957: | Line 1,003: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hirsutism | | style="padding: 5px 5px; background: #F5F5F5;" |Hirsutism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 965: | Line 1,012: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Polycystic Ovarian Disease | | style="padding: 5px 5px; background: #F5F5F5;" |Polycystic Ovarian Disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 973: | Line 1,021: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Delayed puberty | | style="padding: 5px 5px; background: #F5F5F5;" |Delayed puberty | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 981: | Line 1,030: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Parathyroid disorders LP | | style="padding: 5px 5px; background: #F5F5F5;" |Parathyroid disorders LP | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 989: | Line 1,039: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hypoparathyroidism | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 997: | Line 1,048: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Pseudohypoparathyroidism | | style="padding: 5px 5px; background: #F5F5F5;" |Pseudohypoparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,005: | Line 1,057: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Hyperparathyroidism | | style="padding: 5px 5px; background: #F5F5F5;" |Hyperparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,013: | Line 1,066: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Familial hypocalciuric hypercalcemia | | style="padding: 5px 5px; background: #F5F5F5;" |Familial hypocalciuric hypercalcemia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Zand | | style="padding: 5px 5px; background: #F5F5F5;" |Sara Zand | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Complete | | style="padding: 5px 5px; background: #F5F5F5;" |Complete | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In progress | | style="padding: 5px 5px; background: #F5F5F5;" |In progress | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Osteoporosis | | style="padding: 5px 5px; background: #F5F5F5;" |Osteoporosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,029: | Line 1,084: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Zollinger-Ellison syndrome | | style="padding: 5px 5px; background: #F5F5F5;" |Zollinger-Ellison syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,037: | Line 1,093: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Syndrome of inappropriate antidiuretic hormone | | style="padding: 5px 5px; background: #F5F5F5;" |Syndrome of inappropriate antidiuretic hormone | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,045: | Line 1,102: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Autoimmune polyendocrine syndromes | | style="padding: 5px 5px; background: #F5F5F5;" |Autoimmune polyendocrine syndromes | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,053: | Line 1,111: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Amenorrhea | | style="padding: 5px 5px; background: #F5F5F5;" |Amenorrhea | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| Line 1,061: | Line 1,120: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 1,069: | Line 1,129: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 1,077: | Line 1,138: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 1,085: | Line 1,147: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 1,093: | Line 1,156: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 1,101: | Line 1,165: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Revision as of 03:30, 22 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.
System leader: Sogand Goudarzi, M.D.
| Progress | |
|---|---|
| Completed | 76 |
| In progress | 49 |
| Remaining | 3 |
List of Chapters Requiring Content
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Endocrinology | Pheochromocytoma | Assigned | Ifrah | Sogand | In Progress | ||
| Metabolic syndrome X | Assigned | Mina | Sogand | In Progress | |||
| Gestentional Diabetes | |||||||
| Disbetes Insipidus | Assigned | Anahita | Krishna | In Progress | |||
| Hypopitutarism | |||||||
| Sheenhan's Syndrome | |||||||
| Hypogonadism | |||||||
| GH deficiency | |||||||
| Primary hyperaldostronism | |||||||
In progress chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Endocrinology | Metabolic syndrome X | Assigned | Fatemeh Dehghani Fiouzabadi | Sogand | In progress | Sogand | |
| DM Type I | Assigned | Sogand | In progress | ||||
| Disbetes Insipidus | Assigned | Anahita | Krishna | In progress | |||
Completed chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name | |
|---|---|---|---|---|---|---|---|---|
| CVS | Diabetes | Diabetes Landing Page | Assigned | Ramyar | Complete | In progress | ||
| Diabetes Type I | Assigned | Sabawoon | Complete | In progress | ||||
| Diabetes Type II | Assigned | Sahar | Complete | In progress | ||||
| Diabetes insipidus | Assigned | Sahar | Complete | In progress | ||||
| GDM | Assigned | Cafer Zorkon | Complete | In progress | ||||
| Pituitary disorders | Hypopituitarism | Assigned | Mandana | Complete | In progress | |||
| Sheehan Syndrome | Assigned | Javaria Anwer | Farima | Complete | In progress | |||
| Pituitary disorders landing page | Assigned | Hasan | Complete | In progress | ||||
| Hypogonadism | Assigned | Ifeoma | Complete | In progress | ||||
| Pituitary apoplexy | Assigned | Abdelrahman | Complete | In progress | ||||
| Prolactinoma | Assigned | Shadi Ebr | Sahar | Complete | In progress | |||
| GH deficiency | Assigned | Usman Ali Akbar | Sara | Complete | In progress | |||
| Acromegaly | Assigned | Sogand | Complete | In progress | ||||
| Thyroid disorders landing page | Assigned | Maneesha | Complete | In progress | ||||
| Hyperthyroidism landing page | Assigned | Sabawoon | Complete | In progress | ||||
| Graves Disease | Assigned | Ramyar | Complete | In progress | ||||
| Toxic Multinodular goiter | Assigned | Niloofar | Complete | In progress | ||||
| Goiter | Assigned | Ali | Complete | In progress | ||||
| Toxic adenoma | Assigned | Ifrah Fatima | Sogand | Complete | In progress | |||
| Goiter | Assigned | Huda | Complete | In progress | ||||
| Toxic Multinodular goiter | Assigned | Sogand | Complete | In progress | ||||
| Toxic adenoma | Assigned | Huda | Complete | In progress | ||||
| Struma ovarii | Assigned | Fahime | Complete | In progress | ||||
| Hypothyroidism landing page | Assigned | Abdelrahman | Complete | In progress | ||||
| Primary hypothyroidism (hypothyroidism) | Assigned | Maneesha | Complete | In progress | ||||
| Hashimoto thyroiditis | Assigned | Abdelrahman | Complete | In progress | ||||
| Congenital hypothyroidism/Cretinism | Assigned | Aditya | Complete | In progress | ||||
| Secondary hypothyroidism | Assigned | Fahime | Complete | In progress | ||||
| Thyroiditis Landing page | Assigned | Abdelrahman | Complete | In progress | ||||
| Hashimotos Thyroiditis | Assigned | Ahmed | Complete | In progress | ||||
| Dequervian Thyroiditis | Assigned | Hasan | Complete | In progress | ||||
| Riedel's Thyroiditis | Assigned | Sabawoon | Complete | In progress | ||||
| Silent Thyroiditis | Assigned | Ramyar | Complete | In progress | ||||
| Postpartum Thyroiditis | Assigned | Apeksha Gupta | Aditya | Complete | In progress | |||
| Thyroid nodule | Assigned | Soroush | Complete | In progress | ||||
| Sick euthyroid syndrome | Assigned | Fahime | Complete | In progress | ||||
| Thyroid carcinoma landing page | Assigned | Krishna | Complete | In progress | ||||
| Myxedama coma | Assigned | Sara | Complete | In progress | ||||
| Postpartum thyroid dysfunction L. | Assigned | Krishna | Complete | In progress | ||||
| Adrenal disorders landing page | Assigned | Soroush | Complete | In progress | ||||
| Adrenal insufficiency landing page | Assigned | Aditya | Complete | In progress | ||||
| Adrenocortical carcinoma | Assigned | Ali | Complete | In progress | ||||
| CAH L | Assigned | Homa | Complete | In progress | ||||
| 21 hydroxylase def | Assigned | Sogand | Complete | In progress | ||||
| 11 hydroxylase def | Assigned | Ali | Complete | In progress | ||||
| 17 hydroxylase def | Assigned | Homa | Complete | In progress | ||||
| Addisons disease | Assigned | Soroush | Complete | In progress | ||||
| Incidentiloma | Assigned | Anahita Deylamshahi | Krishna | Complete | In progress | |||
| Pheochromocytoma | Assigned | Mohammed Salih | Complete | In progress | ||||
| P hyperaldosteronism(Conn's) | Assigned | Akash Daswaney | Homa | Complete | In progress | |||
| Hypoaldosteronism | Assigned | Ramyar | Complete | In progress | ||||
| Cushing's syndrome/Pseudo-Cushing's syndrome | Assigned | Ifoma | Complete | In progress | ||||
| Secondary Adrenal Insufficiency | Assigned | Sahar | Complete | In progress | ||||
| MEN type I | Assigned | Abdulkareem Lukan | Sahar | Complete | In progress | |||
| MEN type 2 | Assigned | Abdelrahman | Complete | In progress | ||||
| Protein energy maln. (Kwashiorkor, Marasmus) | Assigned | Ibtisam Ashraf | Sahar | Complete | In progress | |||
| Metabolic syndrome | Assigned | Mandana | Complete | In progress | ||||
| Hypoglycemia | Assigned | Niloofar | Complete | In progress | ||||
| Glucaganoma | Assigned | Homa | Complete | In progress | ||||
| Insulinoma (hyperinsulism, hyperinsulinemia) | Assigned | Shivam | Sara | Complete | In progress | |||
| DKA | Assigned | Amandeep | Complete | In progress | ||||
| HONK/HHS | Assigned | Amandeep | Complete | In progress | ||||
| Androgen insensitivity | Assigned | Maneesha | Complete | In progress | ||||
| Gynecomastia | Assigned | Huda | Complete | In progress | ||||
| Hirsutism | Assigned | Ahmed | Complete | In progress | ||||
| Polycystic Ovarian Disease | Assigned | Sahar | Complete | In progress | ||||
| Delayed puberty | Assigned | Abdelrahman | Complete | In progress | ||||
| Parathyroid disorders LP | Assigned | Fahime | Complete | In progress | ||||
| Hypoparathyroidism | Assigned | Qasim Khurshid | Maneesha | Complete | In progress | |||
| Pseudohypoparathyroidism | Assigned | Shakiba Hassanzadeh | Ahmed | Complete | In progress | |||
| Hyperparathyroidism | Assigned | Aditya | Complete | In progress | ||||
| Familial hypocalciuric hypercalcemia | Assigned | Sara Zand | Fahime | Complete | In progress | |||
| Osteoporosis | Assigned | Krishna | Complete | In progress | ||||
| Zollinger-Ellison syndrome | Assigned | Krishna | Complete | In progress | ||||
| Syndrome of inappropriate antidiuretic hormone | Assigned | Fahime | Complete | In progress | ||||
| Autoimmune polyendocrine syndromes | Assigned | Huda | Complete | In progress | ||||
| Amenorrhea | Assigned | Sahar | Complete | In progress | ||||